33 / 61
OAK: OS by PD-L1 subgroup
*Stratified HR for ITT and TC1/2/3 or IC1/2/3, unstratified for all other subgroups
Barlesi, et al. ESMO 2016
0.73
0.75
0.74
0.67
0.41
TC3 or IC3 (16%)
TC2/3 or IC2/3 (31%)
TC1/2/3 or IC1/2/3* (54%)
TC0 and IC0 (45%)
ITT* (n=850)
0.2
2
1
PD-L1 Subgroups
Atezolizumab
Docetaxel
Median OS, months
20.5
8.9
16.3
10.8
15.7
10.3
12.6
8.9
13.8
9.6
In favour of docetaxel
In favour of atezolizumab
HR